Comparing two TACE methods for liver cancer patients with TIPS
Part of Cancer, Digestive system clinical trials.
This trial tests whether a newer targeted chemotherapy bead method (DEB-TACE) works better than standard chemo beads (cTACE) for people with liver cancer who already have a TIPS shunt in place. It aims to find a treatment that controls tumors while being safe for patients with this shunt.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer that is too large or has too many tumors for a liver transplant based on Milan criteria.
- You have a TIPS shunt placed at least 1 month ago to treat bleeding or fluid buildup, and it is still working well.
- Your liver function is good (Child-Pugh class A or B) and your lab results meet certain levels for blood cells, liver enzymes, and kidney function.
- You have not had any cancer treatment in the last 12 months, and you have no other active cancers or serious infections.
- You are not pregnant or planning pregnancy, and you do not have a history of brain metastases or allergies to contrast dye.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of TACE (a procedure that blocks blood supply to the tumor) plus three immunotherapy drugs (sintilimab, bevacizumab, ipilimumab) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination works better than TACE alone.
This trial is for people with advanced liver cancer (HCC) that has spread outside the liver. It tests whether combining a TACE procedure with immunotherapy and anti-angiogenesis drugs can improve outcomes. You must not have had prior systemic therapy and must have received TACE in a specific time window around starting these drugs.
This trial is testing a combination of two immunotherapy drugs (sintilimab and bevacizumab) plus a procedure called TACE (chemoembolization) against a targeted therapy pill (lenvatinib) plus TACE for people with advanced liver cancer. The goal is to see which approach works better to shrink tumors and improve outcomes.
This trial tests a combination of two drugs (lenvatinib and sintilimab) plus a liver-directed treatment (DEB-TACE) with or without another liver treatment (HAIC) for people with large liver cancer (over 7 cm) that has spread into the main blood vessel of the liver. The goal is to see if adding HAIC helps shrink the cancer more effectively.
This trial tests whether a combination of two treatments—chemoembolization (DEB-TACE) plus chemotherapy given through the liver artery (RALOX-HAIC)—works better than chemoembolization alone for people with large liver cancer tumors (over 7 cm). The goal is to see if the combination shrinks tumors more effectively.
This trial tests a combination of two drugs (bevacizumab and sintilimab) versus a standard procedure (TACE) for people with intermediate-stage liver cancer that is too large or widespread for surgery. The goal is to see if the drug combination works better at controlling the cancer.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.